One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Virus Filtration Market

[ 英語タイトル ] Virus Filtration Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083150
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Asahi Kasei Medical Co. Ltd
- Charles River Laboratories International Inc.
- General Electric Company
- Lonza Group Ltd
- Merck KgaA
- Danaher Corporation (Pall Corporation)
- Sartorius AG
- Clean Cell Inc.
- Thermo Fischer Scientific Inc.
- Wuxi Biologics

[Report Description]

The virus filtration market is expected to observe good growth over the forecast period. The major factors attributing to the growth of the virus filtration market are increasing R&D spending, growth in the biopharmaceutical industry, and the adoption of single-use technologies. Also, factors such as the increasing prevalence of chronic diseases are contributing to the growth of the market. The increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, are anticipated to propel the demand for biologics. According to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. This raises the research and development expenditures by biopharmaceutical companies to bring more innovation where virus filtration techniques are highly useful. These factors promote the growth of the virus filtration market.

Key Market Trends

The Kits, Reagents, and Consumables Segment is Expected to Hold the Majority Share of the Market

The kits, reagents, and consumables segment serves as an important category in the virus filtration market. The reagents help to reduce the potential of iatrogenic transmission of pathogenic viruses. In the process evaluation, the reagents help to identify the virus that is likely to contaminate the cell-substrate or any other reagents or materials used in the process.

Qiagen and Merck Millipore are two of the widely known companies for reagents and kits for virus filtration. The samples used in the biopharmaceuticals production may include blood, plasma, serum, or bodily fluids, or any monoclonal antibody and recombinant proteins. Even several biologic and pharmaceutical-based companies are opting to invest more in R&D of vaccines, protein therapeutics, blood products, cellular therapy products, gene therapy products, tissue products, and stem cell products. The demand for these kits and reagents is driving the market studied.

North America Dominates the Market and Expected to do Similar Over the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. This is due to the increasing incidence of diseases and the presence of more number of pharmaceutical companies in the region. In the North American region, the United States holds the largest market share. Additionally, in recent years, there has been increased regulatory scrutiny of incidents related to adventitious viruses in manufacturing processes. Owing to the increased R&D of biopharmaceutical companies, the demand for biologics is expected to drive the viral filtration market, during the forecast period.

Competitive Landscape

The virus filtration market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market studied. With the rising R&D of biopharmaceutical companies and the high prevalence of diseases, few other smaller players are expected to enter into the market studied in the coming years. Some of the major players of the market studied are Asahi Kasei Medical Co. Ltd, Charles River Laboratories International Inc., General Electric Company, Pall Corporation, and Merck KgaA, among others.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Spending
4.2.2 Growth in the Biopharmaceutical Industry
4.2.3 Adoption of Single-use Technologies
4.3 Market Restraints
4.3.1 Stringent Regulations for Validation of Filtration Products
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Filtration Systems
5.1.2 Kits, Reagents, and Consumables
5.1.3 Services
5.2 By Application
5.2.1 Biological Vaccines and Therapeutics Blood and Blood Products Cellular and Gene Therapy Products Tissue and Tissue Products Other Products
5.2.2 Medical Devices
5.2.3 Water Purification
5.2.4 Air Purification
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Contract Research Organizations (CROs)
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Asahi Kasei Medical Co. Ltd
6.1.2 Charles River Laboratories International Inc.
6.1.3 General Electric Company
6.1.4 Lonza Group Ltd
6.1.5 Merck KgaA
6.1.6 Danaher Corporation (Pall Corporation)
6.1.7 Sartorius AG
6.1.8 Clean Cell Inc.
6.1.9 Thermo Fischer Scientific Inc.
6.1.10 Wuxi Biologics




Recommended reports